TargetMol

Heptaplatin

Product Code:
 
TAR-T21307
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T21307-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Heptaplatin, a new platinum derivative with anticancer activity, is used against various cancer cell lines, including cisplatin-resistant cancer cell lines. It has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer.
CAS:
146665-77-2
Formula:
C11H20N2O6Pt
Molecular Weight:
471.373
Purity:
0.98
SMILES:
[Pt++].[O-]C(=O)CC([O-])=O.CC(C)C1OC(CN)C(CN)O1

References

1. Liu W, Chen X, Ye Q, Xu Y, Xie C, Xie M, Chang Q, Lou L. A novel water-soluble heptaplatin analogue with improved antitumor activity and reduced toxicity. Inorg Chem. 2011 Jun 20;50(12):5324-6. doi: 10.1021/ic200436u. Epub 2011 May 20. PubMed PMID: 21598993. 2. Al-Anazi KM, Abou-Tarboush FM, Abdel-Samad MF, Farah MA, Al-Faifi MY, Al-Ahmadi BA. Embryo-feto-toxicity of anticancer drug, heptaplatin in laboratory mice. Pak J Biol Sci. 2010 Sep 15;13(18):896-900. PubMed PMID: 23350163. 3. Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat. 2009 Mar;41(1):12-8. doi: 10.4143/crt.2009.41.1.12. Epub 2009 Mar 31. PubMed PMID: 19688066; PubMed Central PMCID: PMC2699097. 4. Lee JW, Park JK, Lee SH, Kim SY, Cho YB, Kuh HJ. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. Anticancer Drugs. 2006 Apr;17(4):377-84. PubMed PMID: 16549994.